Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NanoCBD
- Development stage
- Phase 1
- Lead developer
- Medlab Group
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Sublingual
01
Overview
NanoCBD is a pharmaceutical-grade, cannabinoid-based formulation developed by Medlab Clinical using its proprietary NanoCelle delivery platform. The product contains cannabidiol (CBD) as the active ingredient, formulated into submicron particles (approximately 21 nm) for oro-buccal (sublingual) administration. This nanomicellar technology facilitates systemic delivery via the facial lymphatics, bypassing the gastrointestinal tract and first-pass hepatic metabolism to enhance bioavailability. While CBD is a phytocannabinoid, Medlab's formulation is described in clinical pipelines as a synthetic cannabinoid antiemetic, specifically targeted for the treatment of chemotherapy-induced nausea and vomiting (CINV). Beyond CINV, NanoCBD has been explored for other indications including anxiety, inflammation, and mental health issues, and has been made available in Australia under the Special Access Scheme (SAS).
- Brand names
- NanoCBD
- Other names
- Medlab NanoCBDNanoCelle CBD
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on NanoCBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoCBD.